{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:40:53Z","timestamp":1782510053514,"version":"3.54.5"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Endocrine science remains underrepresented in European Union research programmes despite the fundamental role of hormone health in human wellbeing. Analysis of the CORDIS database reveals a persistent gap between the societal impact of endocrine disorders and their research prioritisation. At national funding level, endocrine societies report limited or little attention of national research funding towards endocrinology. The EndoCompass project\u2014a joint initiative between the European Society of Endocrinology and the European Society of Paediatric Endocrinology\u2014aimed to identify and promote strategic research priorities in endocrine science to address critical hormone-related health challenges.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Research priorities were established through comprehensive analysis of the EU CORDIS database covering the Horizon 2020 framework period (2014-2020). Expert consultation was conducted to identify key research priorities, followed by broader stakeholder engagement including society members and patient advocacy groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Research priorities encompass re-evaluation of progestins in breast cancer treatment; strategies to disrupt AR signalling in prostate cancer; surveillance for endocrine sequelae in childhood cancer survivors; understanding genotoxic effects on fertility; and management of checkpoint inhibitor endocrinopathies and familial cancer syndromes. Emphasis is placed on precision medicine and metabolic factors in cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This component of the EndoCompass project provides an evidence-based roadmap for strategic research investment. This framework identifies crucial investigation areas into cancer-endocrine pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of these disorders on individuals and society. The findings support the broader EndoCompass objective of aligning research funding with areas of highest potential impact in endocrine health.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf066","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:02:13Z","timestamp":1760691733000},"page":"ii35-ii46","source":"Crossref","is-referenced-by-count":1,"title":["EndoCompass project: research roadmap for endocrine causes and consequences of cancer"],"prefix":"10.1093","volume":"193","author":[{"given":"Jason S","family":"Carroll","sequence":"first","affiliation":[{"name":"Cancer Research UK Cambridge Institute\u2014University of Cambridge , Robinson Way, Cambridge CB2 0RE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-8800","authenticated-orcid":false,"given":"Frederic","family":"Castinetti","sequence":"additional","affiliation":[{"name":"Aix-Marseille Universit\u00e9, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U1251, Marseille Medical Genetics (MMG), Institut Marseille Maladies Rares (MarMaRa) , 13005 Marseille ,","place":["France"]},{"name":"Assistance Publique-H\u00f4pitaux de Marseille (AP-HM), Department of Endocrinology, H\u00f4pital de la Conception, Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019hypophyse HYPO\u2014Department of Endocrinology , 13005 Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Follin","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Faculty of Medicine Lund University, Lund 22100 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7585-1913","authenticated-orcid":false,"given":"Raul M","family":"Luque","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Physiology and Immunology, University of C\u00f3rdoba; Maimonides Institute for Biomedical Research of C\u00f3rdoba (IMIBIC); Hospital Universitario Reina Sof\u00eda (HURS); Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBERobn), 14004 C\u00f3rdoba ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie A","family":"Verrijn Stuart","sequence":"additional","affiliation":[{"name":"Wilhelmina Children's Hospital, University Medical Center , Utrecht 3584 ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5816-0785","authenticated-orcid":false,"given":"Aleksander","family":"Giwercman","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Lund University , Malm\u00f6 20502 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Grozinsky-Glasberg","sequence":"additional","affiliation":[{"name":"Hadassah University Hospital\u2014Neuroendocrine Tumor Unit, ENETS Centre of Excellence, Division of Medicine , Jerusalem, 12000 Jerusalem District ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csilla","family":"Krausz","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences, University of Florence and Careggi University Hospital, 50121 Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-1376","authenticated-orcid":false,"given":"Stavroula A","family":"Paschou","sequence":"additional","affiliation":[{"name":"Endocrine Unit and Diabetes Centre, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens , Athens 11528 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Peeters","sequence":"additional","affiliation":[{"name":"Erasmus University Medical Center Rotterdam\u2014Department of Internal Medicine, Academic Centre for Thyroid Diseases , Rotterdam 3015 ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina R C","family":"Pieterman","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Division of Imaging and Oncology, Department of Endocrine Oncology, Utrecht \u00a0 3584 ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-9569","authenticated-orcid":false,"given":"Pauline","family":"Romanet","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, INSERM, MMG, La Timone University Hospital, Laboratory of Molecular Biology GEnOP\u00e9, BIOGENOPOLE, Marseille \u00a0 13005 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M","family":"Jim\u00e9nez-Vacas","sequence":"additional","affiliation":[{"name":"Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke M","family":"van Santen","sequence":"additional","affiliation":[{"name":"Wilhelmina Children's Hospital, University Medical Center , Utrecht 3584 ,","place":["The Netherlands"]},{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht \u00a0 3584 ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Zibar Tom\u0161ic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, University Hospital Centre Zagreb , Zagreb 10000 ,","place":["Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2025101705020514000_lvaf066-B1","first-page":"649","volume-title":"Diseases of the Breast","author":"Stearns","year":"2014","edition":"5th ed"},{"issue":"12","key":"2025101705020514000_lvaf066-B2","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"24","key":"2025101705020514000_lvaf066-B3","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","article-title":"Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial","volume":"289","author":"Chlebowski","year":"2003","journal-title":"JAMA"},{"issue":"15","key":"2025101705020514000_lvaf066-B4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/jama.2010.1500","article-title":"Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women","volume":"304","author":"Chlebowski","year":"2010","journal-title":"JAMA"},{"key":"2025101705020514000_lvaf066-B5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.maturitas.2015.11.010","article-title":"Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries","volume":"84","author":"Antoine","year":"2016","journal-title":"Maturitas"},{"issue":"10","key":"2025101705020514000_lvaf066-B6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jama.2017.11217","article-title":"Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials","volume":"318","author":"Manson","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"2025101705020514000_lvaf066-B7","doi-asserted-by":"publisher","first-page":"e14314","DOI":"10.15252\/emmm.202114314","article-title":"Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation","volume":"13","author":"Shamseddin","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"3","key":"2025101705020514000_lvaf066-B8","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/ijc.20710","article-title":"Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort","volume":"114","author":"Fournier","year":"2005","journal-title":"Int J Cancer"},{"issue":"1","key":"2025101705020514000_lvaf066-B9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study","volume":"107","author":"Fournier","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2025101705020514000_lvaf066-B10","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025101705020514000_lvaf066-B11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1470-2045(18)30757-5","article-title":"Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial","volume":"20","author":"Denham","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025101705020514000_lvaf066-B12","doi-asserted-by":"publisher","first-page":"e216871","DOI":"10.1001\/jamaoncol.2021.6871","article-title":"Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer: a patient-level data analysis of 3 cohorts","volume":"8","author":"Kishan","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"2025101705020514000_lvaf066-B13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","article-title":"A new old target: androgen receptor signaling and advanced prostate cancer","volume":"62","author":"Westaby","year":"2022","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"12","key":"2025101705020514000_lvaf066-B14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2025101705020514000_lvaf066-B15","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"6","key":"2025101705020514000_lvaf066-B16","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.3892\/mco.2015.645","article-title":"Neuroendocrine differentiation in castration-resistant prostate cancer: a case report","volume":"3","author":"Priftakis","year":"2015","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"2025101705020514000_lvaf066-B17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jamaoncol.2015.4655","article-title":"Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer","volume":"2","author":"Hershman","year":"2016","journal-title":"JAMA Oncol"},{"issue":"11","key":"2025101705020514000_lvaf066-B18","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1158\/1078-0432.CCR-23-3436","article-title":"A signal-finding study of abemaciclib in heavily pretreated patients with metastatic castration-resistant prostate cancer: results from CYCLONE 1","volume":"30","author":"Agarwal","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2025101705020514000_lvaf066-B19","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(22)00637-4","article-title":"Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study","volume":"23","author":"Botta","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025101705020514000_lvaf066-B20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1470-2045(19)30800-9","article-title":"Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study","volume":"21","author":"Suh","year":"2020","journal-title":"Lancet Oncol"},{"issue":"27","key":"2025101705020514000_lvaf066-B21","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2016.66.6545","article-title":"Endocrine abnormalities in aging survivors of childhood cancer: a report from the Childhood Cancer Survivor Study","volume":"34","author":"Mostoufi-Moab","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025101705020514000_lvaf066-B22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1530\/EJE-12-1043","article-title":"Endocrine health conditions in adult survivors of childhood cancer: the need for specialized adult-focused follow-up clinics","volume":"168","author":"Brignardello","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2025101705020514000_lvaf066-B23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.endinu.2017.06.006","article-title":"Endocrine sequelae in childhood cancer survivors. Secuelas endocrinol\u00f3gicas en supervivientes de c\u00e1ncer infantil","volume":"64","author":"Casano Sancho","year":"2017","journal-title":"Endocrinol Diabetes Nutr"},{"issue":"11","key":"2025101705020514000_lvaf066-B24","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.3390\/cancers14112630","article-title":"Endocrine late effects in childhood cancer survivors","volume":"14","author":"Casano-Sancho","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"36","key":"2025101705020514000_lvaf066-B25","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1200\/JCO.2016.67.5025","article-title":"Prevalence and risk factors of early endocrine disorders in childhood brain tumor survivors: a nationwide, multicenter study","volume":"34","author":"Clement","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025101705020514000_lvaf066-B26","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1210\/endrev\/bnab040","article-title":"Hypothalamic-pituitary and other endocrine surveillance among childhood cancer survivors","volume":"43","author":"van Iersel","year":"2022","journal-title":"Endocr Rev"},{"issue":"6","key":"2025101705020514000_lvaf066-B27","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.pcl.2020.08.002","article-title":"Endocrine health in childhood cancer survivors","volume":"67","author":"van Santen","year":"2020","journal-title":"Pediatr Clin North Am"},{"issue":"2","key":"2025101705020514000_lvaf066-B28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000493943","article-title":"Childhood cancer treatments and associated endocrine late effects: a concise guide for the pediatric endocrinologist","volume":"91","author":"Chemaitilly","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"7","key":"2025101705020514000_lvaf066-B29","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2008.13.5293","article-title":"Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial","volume":"26","author":"Laughton","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025101705020514000_lvaf066-B30","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/neuonc\/nov302","article-title":"Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma","volume":"18","author":"Eaton","year":"2016","journal-title":"Neuro Oncol"},{"issue":"10","key":"2025101705020514000_lvaf066-B31","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/sj.bmt.1704481","article-title":"Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood","volume":"33","author":"Bakker","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2025101705020514000_lvaf066-B32","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2025101705020514000_lvaf066-B33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2017.11.005","article-title":"Balancing the benefits and harms of thyroid cancer surveillance in survivors of childhood, adolescent and young adult cancer: recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium","volume":"63","author":"Clement","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"2025101705020514000_lvaf066-B34","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1007\/s00259-022-05762-4","article-title":"Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma\u2014a critical review and evaluation of the existing evidence","volume":"49","author":"Reinecke","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2025101705020514000_lvaf066-B35","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1210\/jcem.85.9.6808","article-title":"Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study","volume":"85","author":"Sklar","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025101705020514000_lvaf066-B36","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1210\/jc.2011-2325","article-title":"Recovery of the hypothalamic-pituitary-adrenal axis in children and adolescents after surgical cure of Cushing's disease","volume":"97","author":"Lodish","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025101705020514000_lvaf066-B37","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-20-0237","article-title":"Clinical considerations for the treatment of secondary differentiated thyroid carcinoma in childhood cancer survivors","volume":"183","author":"van Santen","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2025101705020514000_lvaf066-B38","doi-asserted-by":"publisher","first-page":"P35","DOI":"10.1530\/EJE-21-1186","article-title":"Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement","volume":"186","author":"Boguszewski","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2025101705020514000_lvaf066-B39","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1210\/jc.2018-01175","article-title":"Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an endocrine society clinical practice guideline","volume":"103","author":"Sklar","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025101705020514000_lvaf066-B40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S2213-8587(22)00286-8","article-title":"Risk and determinants of low and very low bone mineral density and fractures in a national cohort of Dutch adult childhood cancer survivors (DCCSS-LATER): a cross-sectional study","volume":"11","author":"van Atteveld","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"2025101705020514000_lvaf066-B41","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1001\/jama.2013.6296","article-title":"Clinical ascertainment of health outcomes among adults treated for childhood cancer","volume":"309","author":"Hudson","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"2025101705020514000_lvaf066-B42","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1210\/jc.2012-2393","article-title":"Longitudinal assessment of bone density and structure in childhood survivors of acute lymphoblastic leukemia without cranial radiation","volume":"97","author":"Mostoufi-Moab","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025101705020514000_lvaf066-B43","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/pbc.23300","article-title":"Bone density in post-pubertal adolescent survivors of childhood brain tumors","volume":"58","author":"Cohen","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2025101705020514000_lvaf066-B44","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/S2666-7568(23)00020-X","article-title":"Frailty and sarcopenia within the earliest national Dutch childhood cancer survivor cohort (DCCSS-LATER): a cross-sectional study","volume":"4","author":"van Atteveld","year":"2023","journal-title":"Lancet Healthy Longev"},{"issue":"16","key":"2025101705020514000_lvaf066-B45","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining childhood and adolescent cancer mortality","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"issue":"19","key":"2025101705020514000_lvaf066-B46","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1001\/jama.2015.4260","article-title":"Prevalence of the metabolic syndrome in the United States, 2003-2012","volume":"313","author":"Aguilar","year":"2015","journal-title":"JAMA"},{"issue":"11","key":"2025101705020514000_lvaf066-B47","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1200\/JCO.20.01765","article-title":"High prevalence of weight gain in childhood brain tumor survivors and its association with hypothalamic-pituitary dysfunction","volume":"39","author":"van Schaik","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025101705020514000_lvaf066-B48","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/ejendo\/lvad139","article-title":"Prevalence, risk factors, and optimal way to determine overweight, obesity, and morbid obesity in the first Dutch cohort of 2338 long-term survivors of childhood cancer: a DCCSS-LATER study","volume":"89","author":"Pluimakers","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2025101705020514000_lvaf066-B49","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1210\/jc.2002-030003","article-title":"Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial","volume":"88","author":"Lustig","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025101705020514000_lvaf066-B50","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-022-00351-z","article-title":"Hypothalamic syndrome","volume":"8","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2025101705020514000_lvaf066-B51","doi-asserted-by":"publisher","first-page":"e704","DOI":"10.1542\/peds.2013-3332","article-title":"Obesity in pediatric ALL survivors: a meta-analysis","volume":"133","author":"Zhang","year":"2014","journal-title":"Pediatrics"},{"issue":"3","key":"2025101705020514000_lvaf066-B52","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.bbmt.2016.12.623","article-title":"Cardiovascular risk factors in survivors of childhood hematopoietic cell transplantation treated with total body irradiation: a longitudinal analysis","volume":"23","author":"Friedman","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2025101705020514000_lvaf066-B53","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(17)30026-8","article-title":"Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium","volume":"18","author":"Skinner","year":"2017","journal-title":"Lancet Oncol"},{"issue":"28","key":"2025101705020514000_lvaf066-B54","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1200\/JCO.2015.64.3288","article-title":"Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium","volume":"34","author":"van Dorp","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025101705020514000_lvaf066-B55","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3390\/antiox12061145","article-title":"Testicular and haematological cancer induce very high levels of sperm oxidative stress","volume":"12","author":"Calamai","year":"2023","journal-title":"Antioxidants"},{"issue":"3","key":"2025101705020514000_lvaf066-B56","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/humrep\/dead269","article-title":"Severe sperm DNA fragmentation may persist for up to 3 years after cytotoxic therapy in patients affected by Hodgkin lymphoma and non-Hodgkin lymphoma","volume":"39","author":"Farnetani","year":"2024","journal-title":"Hum Reprod"},{"key":"2025101705020514000_lvaf066-B57","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1136\/bmj.l5214","article-title":"Risk of prostate cancer for men fathering through assisted reproduction: nationwide population based register study","volume":"366","author":"Al-Jebari","year":"2019","journal-title":"BMJ"},{"issue":"5","key":"2025101705020514000_lvaf066-B58","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/jnci\/djq550","article-title":"Risk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish national registries","volume":"103","author":"St\u00e5hl","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2025101705020514000_lvaf066-B59","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/toxsci\/kfr307","article-title":"Epigenetic alterations in sperm DNA associated with testicular cancer treatment","volume":"125","author":"Chan","year":"2012","journal-title":"Toxicol Sci"},{"issue":"8","key":"2025101705020514000_lvaf066-B60","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/humrep\/dez090","article-title":"The impact of chemo- and radiotherapy treatments on selfish de novo FGFR2 mutations in sperm of cancer survivors","volume":"34","author":"Maher","year":"2019","journal-title":"Hum Reprod"},{"issue":"1","key":"2025101705020514000_lvaf066-B61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"issue":"6","key":"2025101705020514000_lvaf066-B62","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025101705020514000_lvaf066-B63","doi-asserted-by":"publisher","first-page":"100011","DOI":"10.1016\/j.esmoop.2020.100011","article-title":"How we treat endocrine complications of immune checkpoint inhibitors","volume":"6","author":"Paschou","year":"2021","journal-title":"ESMO Open"},{"issue":"2","key":"2025101705020514000_lvaf066-B64","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1210\/endrev\/bnaa031","article-title":"Multiple endocrine neoplasia type 1: latest insights","volume":"42","author":"Brandi","year":"2021","journal-title":"Endocr Rev"},{"key":"2025101705020514000_lvaf066-B65","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.semcancer.2021.03.035","article-title":"Multiple endocrine neoplasia type 2: a review","volume":"79","author":"Mathiesen","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"2025101705020514000_lvaf066-B66","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1530\/EJE-11-0497","article-title":"The genetics of phaeochromocytoma: using clinical features to guide genetic testing","volume":"166","author":"Jafri","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2025101705020514000_lvaf066-B67","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1136\/jmg-2023-109550","article-title":"Update of the UMD-VHL database: classification of 164 challenging variants based on genotype-phenotype correlation among 605 entries","volume":"61","author":"Mougel","year":"2024","journal-title":"J Med Genet"},{"issue":"6","key":"2025101705020514000_lvaf066-B68","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/er.2017-00062","article-title":"New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification","volume":"38","author":"Crona","year":"2017","journal-title":"Endocr Rev"},{"issue":"2","key":"2025101705020514000_lvaf066-B69","doi-asserted-by":"publisher","first-page":"101416","DOI":"10.1016\/j.beem.2020.101416","article-title":"An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma","volume":"34","author":"Buffet","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2025101705020514000_lvaf066-B70","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"2","key":"2025101705020514000_lvaf066-B71","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac001","article-title":"MEN1 surveillance guidelines: time to (re)think?","volume":"6","author":"Newey","year":"2022","journal-title":"J Endocr Soc"},{"issue":"5112","key":"2025101705020514000_lvaf066-B72","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"issue":"7","key":"2025101705020514000_lvaf066-B73","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum Mol Genet"},{"issue":"5311","key":"2025101705020514000_lvaf066-B74","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia-type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science"},{"issue":"7","key":"2025101705020514000_lvaf066-B75","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/6.7.1177","article-title":"Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1","volume":"6","author":"Lemmens","year":"1997","journal-title":"Hum Mol Genet"},{"issue":"20","key":"2025101705020514000_lvaf066-B76","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"issue":"22","key":"2025101705020514000_lvaf066-B77","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"2025101705020514000_lvaf066-B78","doi-asserted-by":"publisher","first-page":"R627","DOI":"10.1530\/ERC-19-0165","article-title":"Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups","volume":"26","author":"Ta\u00efeb","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2025101705020514000_lvaf066-B79","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.surg.2008.08.028","article-title":"Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis","volume":"144","author":"Brauckhoff","year":"2008","journal-title":"Surgery"},{"issue":"3","key":"2025101705020514000_lvaf066-B80","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S2213-8587(18)30336-X","article-title":"Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study","volume":"7","author":"Castinetti","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2025101705020514000_lvaf066-B81","doi-asserted-by":"publisher","first-page":"T91","DOI":"10.1530\/ERC-15-0268","article-title":"15 YEARS OF PARAGANGLIOMA: clinical manifestations of paraganglioma syndromes types 1-5","volume":"22","author":"Benn","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2025101705020514000_lvaf066-B82","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000508374","article-title":"Health-related quality of life in patients with multiple endocrine neoplasia type 1","volume":"111","author":"van Leeuwaarde","year":"2021","journal-title":"Neuroendocrinology"},{"issue":"5","key":"2025101705020514000_lvaf066-B83","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1089\/thy.2016.0148","article-title":"Assessment of depression, anxiety, quality of life, and coping in long-standing multiple endocrine neoplasia type 2 patients","volume":"27","author":"Rodrigues","year":"2017","journal-title":"Thyroid"},{"issue":"2","key":"2025101705020514000_lvaf066-B84","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cen.14823","article-title":"Frequency and impact of musculoskeletal symptoms on quality of life in MEN2B","volume":"98","author":"Henderson","year":"2023","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/Supplement_2\/ii35\/64633671\/lvaf066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/Supplement_2\/ii35\/64633671\/lvaf066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:02:15Z","timestamp":1760691735000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/Supplement_2\/ii35\/8281958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":84,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2025,10,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf066","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10]]}}}